GlobeNewswire

Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin

Share
  • Early combination treatment strategy with vildagliptin (Galvus®) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients[1],[2]
     
  • The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diabetes (T2DM)[1]
     
  • Novartis is committed to optimizing patient management of T2DM to achieve better glycemic control and favorable long-term clinical outcomes 

Basel, September 18, 2019 — Novartis today announced the key results from the Phase IV clinical study VERIFY evaluating the long-term efficacy and safety of early combination treatment strategy with metformin plus vildagliptin (dipeptidyl peptidase-4 [DPP-4] inhibitor) compared to the traditional stepwise approach with metformin as initial therapy followed by vildagliptin, added at the time of metformin failure[1],[2]. The key study findings were presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting and published simultaneously in The Lancet.

VERIFY is a unique study designed to determine durability, over a pre-specified five-year follow-up of early use of combination therapy strategy with vildagliptin-metformin. The study was conducted across 254 centers in 34 countries and involved 2001 treatment-naïve diverse individuals recently diagnosed with T2DM (HbA1c between 6.5–7.5% [48–58 mmol/mol])[1],[2].

In the randomized, double-blind Phase IV study (ClinicalTrials.gov Identifier: NCT01528254), early combination therapy of vildagliptin (50 mg, twice daily) and metformin (individually, 1000–2000 mg, daily) met the primary endpoint with a statistically significant 49% reduction in the relative risk for time to initial treatment failure (HbA1c >= 7.0% twice, consecutively, 13 weeks apart), versus metformin alone (HR: 0.51, 95% CI [0.45, 0.58]; P<0·0001)[1],[2].

The combination treatment strategy also showed a lower frequency of secondary failure when all patients were receiving combination therapy (HR: 0.74, 95% CI [0.63, 0.86]; P<0.0001). Furthermore, patients treated with early combination had consecutively lower HbA1c levels (below 6.0%, 6.5% or 7.0%) for 5 years versus those receiving combination therapy only after metformin monotherapy failure[1].

“The initial findings from the VERIFY study uniquely demonstrate that early intervention with a combination therapy strategy provides greater and durable long-term benefits for patients. The currently recommended initial monotherapy approach with later treatment intensification in type 2 diabetes management is now shown to be an inferior strategy,” said Professor David Matthews, EASD President and Emeritus Professor of Diabetic Medicine, University of Oxford, UK.

The overall safety and tolerability profile was similar between the treatment approaches, with no unexpected or new safety findings reported[1].

“Despite type 2 diabetes having become an epidemic with growing mortality and morbidity rates, there is a distinct lack of optimized management strategies at diagnosis that can induce durability and slow down disease progression,” said Marcia Kayath, Global Head Medical Affairs and Chief Medical Officer, Novartis Pharmaceuticals. “These promising results from the VERIFY study have the potential to improve patient outcomes and the way in which we treat type 2 diabetes in the future”.

Additional pre-defined secondary analyses of the VERIFY study results are ongoing and data will be disclosed over the coming months at international and local medical congresses and in scientific journals.

About vildagliptin/metformin combination (Eucreas® /Galvusmet®)
The combination of these two anti-diabetic agents with complementary mechanisms of action provides superior efficacy and allows patients to reach glycemic targets without increasing the risk of hypoglycemia, weight gain and other CV risk factors[3]. Vildagliptin-metformin combination was the first single-pill dual therapy of a DPP-4 inhibitor with metformin approved in Japan and Europe[4]. The vildagliptin and metformin dual therapy is used when the patient’s T2DM is insufficiently controlled by metformin monotherapy[5].

About vildagliptin (Galvus®)
Vildagliptin is approved as an oral treatment for adults with T2DM in more than 120 countries, including the EU, Japan, Latin America and Asia-Pacific. Vildagliptin is approved for use as monotherapy, dual therapy in combination with metformin, sulfonylurea (SU) or a thiazolidinedione, as a triple oral therapy in combination with a SU and metformin or as an add-on to insulin (with or without metformin)[4],[5],[6].

Vildagliptin is a selective and potent DPP-4 inhibitor that acts by preventing the usually rapid degradation of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which in turn, enhances the alpha- and ß-cell sensitivity to glucose and inhibits glucagon secretion, thereby improving glycemic control in T2DM[7],[8],[9],[10]. Vildagliptin has been widely studied in randomized clinical trials but it also has an extensive pool of evidence in real world settings within diverse patient populations across the disease continuum[11].

About metformin
Metformin hydrochloride is widely-used and is the recommended first-line therapy in patients with newly-diagnosed T2DM either immediately after diagnosis, or in those not able to achieve glycemic targets despite diet and other lifestyle interventions[12].

Despite its discovery already in 1922, the exact mode of action for metformin is not yet known. However, its effect in management of diabetes is through reduction of glucose output in the liver and secondarily, through increase of glucose uptake in the peripheral tissues. However, recent data suggests that some clinical activity may also arise from the synthesis and stimulation of intestinal release of incretin hormones[12],[13].

About VERIFY study[1],[2]
The VERIFY study is a five-year, multi-center, randomized, double-blind Phase IV trial designed to assess the durability of glycemic control of a combination regimen strategy with vildagliptin and metformin compared with standard-of-care monotherapy approach with metformin initiated in treatment-naïve, diverse patients with recently diagnosed T2DM (HbA1c between 6.5-7.5% [48–58 mmol/mol]).

The study involved 2001 patients prescribed with stable dose of metformin (1000–2000 mg daily) 4 weeks prior to or during the trial and randomized (1:1) to receive additional vildagliptin 50 mg twice daily or placebo. Dose adjustment of metformin in both treatment arms was permitted during the first 4 weeks in the trial, to allow adjustment to a dose of up to 2000 mg/day or the maximum tolerable dose of at least 1000 mg/day post-randomization. If the initial treatment strategy failed to maintain an HbA1c level <7.0%, participants in the metformin monotherapy group were administered vildagliptin 50 mg twice daily in place of the placebo.

The primary endpoint was time to confirmed initial treatment failure, defined as HbA1c >=7% at two consecutive scheduled visits, 13 weeks apart. Secondary endpoints included rate of loss of glycemic control, HbA1c development over time, rate of loss in glycemic control in fasting plasma glucose, rate of loss of beta cell function from baseline to end of study, rate of change in insulin sensitivity from baseline to end of study, and rate of adverse events. Exploratory endpoints include adjudication of cardiovascular events and changes in glucose homeostasis (HOMA).

About T2DM
Diabetes mellitus is a condition characterized by increasing hyperglycemia due to defects in both insulin production and insulin sensitivity[14]. The prevalence of diabetes has quadrupled in the past three decades with approximately 1 in 11 adults now having the disease worldwide, of these approximately 90% have T2DM[15]. Additionally, factors such as glucose intolerance (pre-diabetes), underdiagnosed and/or delayed diagnosis of T2DM are causing a rapid increase in disease burden. This is especially seen in developing countries, which contributes to the continuously growing burden of diabetes. The International Diabetes Federation estimates that there is a new diagnosis every 6 seconds somewhere in the world[16].

After diagnosis, the majority of patients are unable to achieve and maintain the recommended glycemic control targets as defined by the guidelines[17].  This universal lack of achievement of glycemic control is partly attributed to the current treatment paradigm involving sequential monotherapy, frequent early treatment failure and delayed therapy intensification leading to prolonged periods of sustained hyperglycemia. Combatting inertia in treatment intensification could also include a strategy of earlier and more comprehensive introduction combination therapy approach[11],[18].

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References
      [1]    Novartis. Data on file.
      [2]    NIH: ClinicalTrials.gov. VERIFY: A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus. Available at: https://clinicaltrials.gov/ct2/show/NCT01528254. Accessed August 2019.
      [3]    Halimi S, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008: 4(3): 481-492.
      [4]    Novartis. Corporate Factsheet: Innovative Medicines. Available at: https://www.novartis.com/news/novartis-corporate-fact-sheet/innovative-medicines-en. Accessed August 2019.
      [5]    EMA Galvus SmpC. Available at: https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information_en.pdf. Accessed August 2019.
      [6]    Profit L, et al. Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2008: 3(1): 13-30.
      [7]    Pan CY & Wang XL. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag 2013: 9: 247-257.
      [8]    Garber AJ & Sharma MD. Update: vildagliptin for the treatment of Type 2 diabetes. Expert Opin Investig Drugs 2008: 17(1): 105-113.
      [9]    Stamataros G & Schneider SH. Vildagliptin in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2011: 12(12):1967-1973.
      [10]  Villhauer EB, et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:  A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J Med Chem 2003; 46(13): 2774-2789.
      [11]  Strain WD & Paldánius PM. Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. Eur Endocrinol 2017: 13(2): 62-67.
      [12]  Sanchez-Rangel E & Inzugghi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017: 60(9): 1586-1593.
      [13]  Rena G, et al. The mechanisms of action of metformin. Diabetologia 2017: 60(9): 1577-1585.
      [14]  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013: 36(Suppl 1): S67-S74.
      [15]  Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018: 14(2): 88-98.
      [16]  International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. Available at: https://diabetesatlas.org/resources/2017-atlas.html. Accessed August 2019.
      [17]  Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Disease Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018 Dec; 41(12): 2669-2701
      [18]  Zinman, B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011: 124(Suppl 1): S19-S34.

# # #

Novartis Global External Communications
E-mail: media.relations@novartis.com

Peter Zuest
Novartis Global External Communications
+41 61 324 6383 (direct)
+41 79 899 9812 (mobile)
peter.zuest@novartis.com 

 

 

Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Meghan O’Donnell
Global Head Communications and Patient Advocacy,  Cardio-Renal-Metabolism
+41 61 324 9136 (direct)
+41 79 797 9102 (mobile)
meghan.odonnell@novartis.com

 

Ruth Kuguru
Head of Communications and Patient Advocacy, APMA Region
+65 67226010 (direct)
+65 9238 6791 (mobile)
ruth.kuguru@novartis.com

 

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America  
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 778 3258

 
Thomas Hungerbuehler +41 61 324 8425    
Isabella Zinck +41 61 324 7188    

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen1.6.2020 19:30:00 CESTPressemelding

Företagsmeddelande, insiderinformation, Helsingfors 1 juni 2020 kl. 20.30 (EEST) Nexstim Abp: Preliminärt utfall av den lyckade företrädesemissionen FÅR EJ PUBLICERAS ELLER SPRIDAS DIREKT ELLER INDIREKT I FÖRENTA STATERNA, AUSTRALIEN, SYDAFRIKA, HONGKONG, JAPAN, KANADA, SINGAPORE ELLER NÅGON ANNAN STAT DÄR SPRIDNINGEN ELLER PUBLICERINGEN STRIDER MOT LAGEN. Teckningstiden för Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) företrädesemission om cirka 2,3 miljoner euro (”emissionen”) avslutades 25 maj 2020 i Sverige och 27 maj 2020 i Finland. Enligt det preliminära emissionsutfallet övertecknades emissionen och cirka 273 procent av de tilldelade aktierna tecknades. Av de tilldelade 376 719 780 nya aktierna (”emissionsaktierna”) tecknades 336 033 654 emissionsaktier (cirka 89,2 procent av emissionsaktierna) med företrädesrätt och 40 686 126 emissionsaktier (cirka 10,8 procent av emissionsaktierna) tilldelas i enlighet med emissionsvillkoren. Enligt det preliminära emissio

Nexstim Plc: Preliminary results of the successful rights issue1.6.2020 19:30:00 CESTPress release

Company announcement, inside information, Helsinki, 1 June 2020 at 8:30 pm (EEST) Nexstim Plc: Preliminary results of the successful rights issue NOT FOR PUBLICATION OR DISTRIBUTION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, SOUTH AFRICA, HONG KONG, JAPAN, CANADA OR SINGAPORE, OR IN ANY OTHER COUNTRY WHERE PUBLICATION OR DISTRIBUTION WOULD BE AGAINST THE LAW. The subscription period of Nexstim Plc’s (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “the Company”) rights issue of approximately EUR 2.3 million (“the Share Issue”) ended on 25 May 2020 in Sweden and on 27 May 2020 in Finland. The preliminary results indicate that the Share Issue was oversubscribed and a total of 273% shares were subscribed for of the shares offered. Of the 376,719,780 new shares offered in the Share Issue (“the Offer Shares”), 336,033,654 Offer Shares (approximately 89,2% of the Offer Shares) were subscribed using subscription rights which means that 40,686,126 Offer Shares (approximately 10.8% of

Kinnevik: Valberedning inför årsstämman 20211.6.2020 17:00:00 CESTPressemelding

I enlighet med beslutet vid årsstämman 2020 i Kinnevik AB (publ) (”Kinnevik”) har en valberedning sammankallats, bestående av ledamöter utsedda av Kinneviks röstmässigt största aktieägare. Valberedningen består av Cristina Stenbeck utsedd av Verdere S.à r.l. och CMS Sapere Aude Trust, Hugo Stenbeck utsedd av Alces Maximus LLC, James Anderson utsedd av Baillie Gifford, Anders Oscarsson utsedd av AMF Försäkring & Fonder, Marie Klingspor och Ramsay Brufer utsedd av Alecta. Anders Oscarsson har utsetts till ordförande i valberedningen. Information om valberedningens arbete finns på Kinneviks hemsida, www.kinnevik.com. Aktieägare som önskar lämna förslag till valberedningen kan göra det i skrift till agm@kinnevik.com eller till Valberedningen, Kinnevik AB, Box 2094, 103 13 Stockholm. För ytterligare information, besök www.kinnevik.com eller kontakta: Torun Litzén, Informations- och IR-chef Telefon +46 (0)70 762 00 50 Email press@kinnevik.com Kinnevik är ett sektorfokuserat investmentbolag s

Kinnevik: Nomination committee ahead of the 2021 Annual General Meeting1.6.2020 17:00:00 CESTPress release

In accordance with the resolution of the 2020 Annual General Meeting in Kinnevik AB (publ) (“Kinnevik”), a Nomination Committee has been convened comprising members appointed by Kinnevik’s largest shareholders in terms of voting interest. The Nomination Committee comprises Cristina Stenbeck appointed by Verdere S.à r.l. and CMS Sapere Aude Trust, Hugo Stenbeck appointed by Alces Maximus LLC, James Anderson appointed by Baillie Gifford, Anders Oscarsson appointed by AMF Insurance & Funds, Marie Klingspor and Ramsay Brufer appointed by Alecta. Anders Oscarsson has been appointed Committee Chairman. Information about the work of the Nomination Committee can be found on Kinnevik’s website at www.kinnevik.com. Shareholders wishing to submit proposals to the Nomination Committee can do so in writing to agm@kinnevik.com or to the Nomination Committee, Kinnevik AB, P.O. Box 2094, SE-103 13 Stockholm Sweden. For further information, visit www.kinnevik.com or contact: Torun Litzén, Director Inve

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER1.6.2020 16:20:00 CESTPress release

Bid procedure on 3 June 2020 Certificate:Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 3 December 2020 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 25 May 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 3 June 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SE

Real People Investment Holdings Limited – Appointment of Director1.6.2020 15:00:00 CESTPress release

The board of Real People Investment Holdings Limited has elected to appoint Mr Ralph Buddle as a non-executive director of the company, with effect from 1 June 2020. Mr Buddle is an experienced senior executive and chartered accountant with 35 years’ experience in retail and FMCG. With a background in corporate finance, M&A and strategy, he also has significant investor relations and corporate governance experience within the JSE Top-40 listed environment. * * * * * * * For further information, please contact: Neil Grobbelaar, Group Chief Executive Officer Email: ctaylor@realpeople.co.za Phone number: +27 82 772 5481 The information was submitted for publication, through the agency of the contact person set out above, on June 1st, 2020 at 15:00 CET Attachment RPIH Press Release - Appointment of director 20200528